a developer of antibody drug conjugates to improve patient outcomes in multiple oncology indications
Industry Biotechnology
A.I.dvisor indicates that over the last year, MRSN has been loosely correlated with VRDN. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if MRSN jumps, then VRDN could also see price increases.
Ticker / NAME | Correlation To MRSN | 1D Price Change % | ||
---|---|---|---|---|
MRSN | 100% | -8.23% | ||
VRDN - MRSN | 37% Loosely correlated | -1.43% | ||
NTLA - MRSN | 36% Loosely correlated | -3.65% | ||
ALLO - MRSN | 35% Loosely correlated | -4.56% | ||
MLYS - MRSN | 35% Loosely correlated | -3.71% | ||
ACET - MRSN | 35% Loosely correlated | +2.05% | ||
More |
Ticker / NAME | Correlation To MRSN | 1D Price Change % |
---|---|---|
MRSN | 100% | -8.23% |
biotechnology theme (248 stocks) | 38% Loosely correlated | +5.56% |
drugs theme (265 stocks) | 38% Loosely correlated | +5.37% |
cancer theme (87 stocks) | 37% Loosely correlated | +0.89% |
antibody theme (6 stocks) | 16% Poorly correlated | +3.08% |